Off-market insider net buying at Eupraxia Pharmaceuticals (T:EPRX)

Llc Manchester Management Company, a 10% Holder, acquired 122,927 Common Shares on an indirect ownership basis for registered holder Jeb Partners L.P. and 2,511,122 Common Shares on an indirect ownership basis for registered holder Manchester Explorer, L.P. at a price of $2.050 through a private transaction on April 20th, 2022. The insider also acquired 122,927 Warrants on an indirect ownership basis for registered holder Jeb Partners L.P. and 2,511,122 Warrants on an indirect ownership basis for registered holder Manchester Explorer, L.P. with an exercise price of $3.000 for 48 moths. This represents a $5,399,800 net investment into the company's shares and an account share holdings change of greater than 100%.

Eupraxia Pharmaceuticals is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Eupraxia Pharmaceuticals Inc. is a Canada-based clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its lead product candidate, EP-104IAR, is designed to meet the unmet medical need and market demand for long-lasting pain relief for knee osteoarthritis (OA). EP-104IAR contains a solid core of the active ingredient Fluticasone Propionate (FP) with an outer layer of the biocompatible polymer, PVA. In addition to EP-104IAR, the Company is also developing a pipeline of earlier-stage long-acting formulations. It develops pipeline candidates for a range of indications, such as post-surgical pain (EP-105), and post-surgical site infections (EP-201). The Company has completed a phase I, double-blind, placebo-controlled clinical study at three sites in Canada.